Verrica Pharmaceuticals has received the company’s third Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its New Drug Application for the molluscum contagiosum treatment candidate VP-102.
https://www.pharmalive.com/wp-content/uploads/2021/08/FDA-Slams-Sesen-Bio-with-CRL-for-Bladder-Cancer-Drug-BioSpace-8-17-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-05-25 12:31:102022-05-25 12:34:03FDA hits Verrica with third CRL for lead drug candidate VP-102
